Clinical outcome of PSMA-guided radiotherapy for patients with oligorecurrent prostate cancer

PURPOSE: First-line treatment of patients with recurrent, metastatic prostate cancer involves hormone therapy with or without additional systemic therapies. Prostate-specific membrane antigen (PSMA) positron emission tomography (PET)/computed tomography (CT) allows the detection of oligometastatic d...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Nucl Med Mol Imaging
Main Authors: Stefan A. Koerber, Katharina Sprute, Clemens Kratochwil, Erik Winter, Matthias F. Haefner, Sonja Katayama, Ingmar Schlampp, Klaus Herfarth, Klaus Kopka, Ali Afshar-Oromieh, Stefanie Zschaebitz, Tim Holland-Letz, Peter L. Choyke, Dirk Jaeger, Markus Hohenfellner, Uwe Haberkorn, Juergen Debus, Frederik L. Giesel
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2020
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7835298/
https://ncbi.nlm.nih.gov/pubmed/32405735
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00259-020-04777-z
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados